Alto Neuroscience (NYSE:ANRO - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter.
Alto Neuroscience Stock Up 0.5 %
ANRO stock traded up $0.02 during trading on Friday, hitting $3.18. The stock had a trading volume of 137,921 shares, compared to its average volume of 362,045. Alto Neuroscience has a 1-year low of $2.67 and a 1-year high of $18.35. The company's 50 day moving average price is $3.79 and its two-hundred day moving average price is $6.44. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.
Alto Neuroscience Company Profile
(
Get Free Report)
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
